Abstract

**Objective:** The objective of this work is to summarize the immunological treatment of neurological diseases, describing the present situation and the challenges and opportunities the future will present.

**Method:** After topographically classifying the autoimmune neurological pathologies, a bibliographic analysis is made to present the most relevant ones regarding the available immunotherapeutic options. Likewise, new neurological entities that will be future candidates for immunotherapy are discussed.

**Results:** There is a large number of neurological diseases with an autoimmune basis, even though their pathophysiology is, sometimes, only partially understood. Only a few randomized controlled clinical trials support the evidence of the immunotherapies with which we treat some of these diseases. This situation is rapidly changing among entities like multiple sclerosis where level 1 of evidence clinical studies are today’s standard. Alzheimer’s disease and migraine are two of the most prevalent conditions that are being incorporated to the group of diseases candidates for immunotherapy.

**Conclusions:** Taking into account the rapidly growing number of immunological therapies and of neurological diseases potentially receiving them, an adequate evaluation of the impact these treatments will have on social and healthcare system grounds is necessary to reach compromises and consensus among all the professionals involved in the management of these pathologies.

**KEYWORDS**

Immunotherapy; Neurologic disorders; Autoimmune diseases; Multiple sclerosis; Neuromyelitis optica; Alzheimer disease; Migraine; Movement disorders.

**PALABRAS CLAVE**

Inmunoterapia; Patologías neurológicas; Enfermedades autoinmunes; Esclerosis múltiple; Neuromielitis óptica; Enfermedad de Alzheimer; Migraine; Trastornos del movimiento.


Introduction

During the past decades there has been a significant increase in our knowledge about the physiopathology of neurological conditions. Within these, diseases with immunological origin are responsible for major morbidity and even mortality, affecting the central nervous system (CNS) (multiple sclerosis [MS], neuromyelitis optica [NMO], limbic encephalitis…) and/or the peripheral system (Guillain-Barré syndrome [GBS], myasthenia gravis…) (Table 1). Overall, all these nosological conditions cause a major impact on patients and those around them but, given that some of them have a high prevalence, there can also be an impact for the public health system.

The constant study of new treatment targets has allowed a more effective treatment of neurological diseases with immunological origin, with medications more specific for each condition, such as the case of MS, but it has also led to widening the range of diseases that can be potentially treated in this way. Thus, a deeper knowledge of the physiopathological mechanisms of conditions so prevalent as Alzheimer’s disease or migraine, so far not included in the group of “immune-mediated diseases”, has shown the role of immunomodulation treatments for their management, not only as hypotheses for the future but also as a short-term reality.

This article is intended as a brief review of the current situation of immunotherapy in neurological conditions, and to present some of the new therapeutic targets that will be offered to us in the near future.

Multiple sclerosis

MS is an inflammatory and demyelinating condition of the CNS. Its prevalence in Spain is of 91.2/100,000, and there has been a confirmed increase in its prevalence during the past decades. It presents two evolution forms. The relapsing remitting form (RRMS) consists in the presence of relapses of focal and acute CNS inflammation which cause new symptoms, with or without irreversible accumulated sequelae (and without any clinical worsening when there are no relapses). The progressive form is defined by a worsening in the clinical status of the patient when there are no relapses. The treatment of the disease, besides symptomatic treatment and physiotherapy, is divided into the management of relapses and the use of “disease modifying drugs”.

Relapses are treated with glucocorticoids at high doses in short courses, typically 1 daily gram of intravenous methylprednisolone during 3 to 5 days. A multicenter, randomized, double-blind controlled clinical trial confirmed the non-inferiority of oral methylprednisolone 1,000 mg/day/3 days, therefore, oral treatment could be an alternative option to intravenous administration. In cases resistant to corticoid therapy, a plasmapheresis course will be effective in 72% of cases.

Disease-modifying treatment is intended to improve the functional prognosis of patients at medium and long term. Until the launch of immunomodulatory treatments specific for MS management, treatment consisted in immunosuppressants used for other conditions. In fact, azathioprine and mitoxantrone have the approved indication for their use in this disease.

When interferon-beta 1b appeared in the 90’s decade, there was a revolution in MS treatment. Currently we have 17 different products for treatment of relapsing remitting MS, three for the treatment of secondary progressive forms, and one recently approved for the treatment of the primary progressive disease. All these have demonstrated their efficacy in randomized and controlled clinical trials, and this has led to the approval of the specific indication in their product specifications. Figure 1 shows the molecules used for treatment of MS, according to their order of launch. It is worth highlighting the increasing frequency with which new molecules for this indication are being approved by regulatory agencies.

Both interferons-β and glatiramer acetate are being used for the past two decades with moderate efficacy and a verified safety profile, making them adequate as first line treatment. There is only correct acceptance by patients, because the way of administration is subcutaneous or intramuscular. For this reason, there has been a search for formulations with lower frequency of administration, such as pegylated interferon-β or glatiramer acetate 40 mg. Widely used, this type of medications is not always effective or well tolerated in all patients, therefore, research has focused on finding medications which are more potent and ways of administration which are more convenient for patients.

Teriflunomide and dimethyl fumarate, which are oral medications, currently allow treating MS patients without using parenteral administration.

Teriflunomide acts by a reversible inhibition of the dihydroorotate dehydrogenase enzyme, highly expressed in activated lymphocytes, causing a reduction in the proliferation of activated lymphocytes T and B. Teriflunomide has demonstrated efficacy in RRMS treatment both in controlled and randomized clinical trials vs. placebo and in the clinical trial vs. interferon β1a 44 μg three times per week. Its safety profile is favorable but there is potential liver toxicity, which requires strict monitoring. It cannot be used in pregnant women until two years after discontinuation, because there is high teratogenic risk; there is a procedure for fast elimination which allows to reduce the product concentration below the risk considered minimal for the fetus (<0.02 μg/mL). Dimethyl fumarate, with a mechanism of action still not completely understood, has demonstrated its efficacy in two clinical trials. Its gastrointestinal tolerability can be troublesome, unlike its other characteristic side effect: flushing. Some cases of progressive multifocal leukoencephalopathy (PML) have been published in association with this drug, which forces to conduct a periodical monitoring of the total lymphocyte count; it is recommended to interrupt the use of dimethyl fumarate if this count goes below 500/μL persistently during 6 continuous months. In terms of finding more effective drugs, medications such as alemtuzumab, fingolimod and natalizumab are those associated with higher efficacy for preventing relapses; natalizumab seems to be associated to a higher extent with a lower progression of disability. Natalizumab is a recombinant humanized monoclonal antibody which binds with integrin alpha-4 beta-1 and blocks the interaction with the vascular cell adhesion molecule 1 (VCAM-1), thus preventing the migration to the CNS of mononuclear leukocytes through the endothelium of the blood-brain barrier.

Its use has been associated with the development of PML in patients with positive test results for anti-JC virus antibodies, and this risk will be higher with a longer time of treatment, and also if the patient was treated with immunosuppressants before natalizumab. This fact is a major limitation for the use of this medication. Alemtuzumab has been evaluated in three clinical trials vs. an active comparator: interferon β1a 44 μg three times per week. A Cochrane evaluation reached the conclusion that alemtuzumab is significantly more effective than interferon β. Alemtuzumab has not been associated with PML development, but there have been potentially severe reactions to the intravenous infusion, infec-
tions, and autoimmune events which require strict monitoring. Fingolimod is a sphingosine-1-phosphate receptor modulator with oral administration, which has demonstrated its efficacy and safety for RMS treatment in three Phase III clinical trials. It is more effective than weekly interferon β 30 µg in the reduction of relapse parameters and magnetic resonance imaging. Given that fingolimod also interacts with different subtypes of sphingosine-1-phosphate receptors (S1PR1, S1PR2, S1PR3, S1PR4, S1PR5), there is a risk of brachycardia and QT-interval prolongation, which requires patient monitoring during the first dose. An increase in blood pressure has been described, as well as macular edema, liver toxicity and some cases of PML, which require a careful monitoring of patients\(^a\). With the aim to improve the safety profile of sphingosine-1-phosphate receptor modulators, there are various molecules under research with higher selectivity for the S1PR1 receptor, which is the cause of the effect on lymphocytes, and has no effects on other organs or systems. The agents currently under development are: siponimod, ponesimod, ozanimod, ceralifimod, GSK2018682. These results could lead siponimod to become, alongside interferon β1b and mitoxantrone, the fourth medication with specific indication for the treatment of secondary progressive MS.

In this overview of the near future of MS treatment, we cannot leave out two medications recently approved by the European Medicines Agency: ocrelizumab and oral cladribine. Ocrelizumab is a humanized anti-CD20 monoclonal antibody that has demonstrated high efficacy in RMS treatment, based in two randomized and controlled clinical trials. It has also confirmed, and this is a milestone in MS treatment, its ability to delay the accumulated disability in patients with primary progressive MS\(^b\). Thus, it has the indication for RMS but also for the treatment of those adult patients with early primary progressive MS who present inflammatory activity in imaging tests. Other anti-CD20 antibodies have already been used off-label for RMS treatment (rituximab), or are currently in the stage of clinical development (ofatumumab). Oral cladribine\(^c\) causes gradual lymphocyte depletion over the weeks, not associated with cell lysis, with higher impact on B cells than on T cells, and with reconstitution of the count of said cell lines throughout the months. In this way, when administered in two bimonthly cycles separated by one year, it acts as an inducer drug, not causing the prolonged immunosuppression of other previously mentioned medications which require uninterrupted treatment. The efficacy of cladribine has been demonstrated in two randomized and controlled Phase III clinical trials. Its main side effect is lymphopenia, associated with its mechanism of action; but it does not seem to be associated with an increase in neoplasia or infections vs. the control, except for the case of herpes zoster infections. Cladribine is indicated for adult patients with recurrent MS with high clinical or radiological activity.

The way of administration, potential effects, and recommended monitoring for the medications mentioned in this review appear summarized in Table 2.

### Neuromyelitis optica

NMO is an inflammatory demyelinating condition, anti-aquaporin 4 antibody-mediated (NMO-IgG). It affects specifically the spinal cord and the optic nerves. Its prevalence in Spain is of 1.5/100,000 inhabitants, and therefore less frequent than MS, but potentially more severe in the majority of cases.

Treatment of inflammatory relapses is conducted with 1 gram of intravenous methylprednisolone per day during 3 to 5 days, though its evidence comes from studies with MS or optic neuritis patients. Those patients who show no improvement with the previous regimen are treated with plasmapheresis\(^2\) or intravenous human immunoglobulin\(^3\).

Regarding maintenance treatment, intended to prevent new relapses and accumulated disability, treatment will be typically initiated with azathioprine or mycophenolate mofetil, while the patient receives treatment with IV methylprednisolone, due to the time that these medications will take to start acting. Another first line option is rituximab\(^4\). Methotrexate would be reserved for those patients who don’t tolerate the previous treatments, or those for whom these are not effective\(^5\).

Other potential treatments, but more dubious in terms of efficacy or toxicity, are tacrolimus, cyclosporine, mitoxantrone, and cyclophosphamide\(^6\). It is worth pointing out here that some disease-modifying drugs for MS, such as interferon β1b, natalizumab\(^8\), and fingolimod\(^9\), will lead to a worsening in the evolution of NMO; therefore, it is essential to conduct an adequate differential diagnosis between both nosological entities.

In terms of new treatment options, various monoclonal antibodies are being evaluated for their use in NMO. Tocilizumab is a recombinant humanized anti-IL-6, which causes deletion of plasmablasts (which are CD20+, and therefore are not affected by rituximab); it has shown efficacy in some isolated cases\(^20\) and in a Phase IV study\(^21\). On the other hand, eculizumab inhibits the complement pathway, preventing the cleavage of C5 into C5a and C5b, and therefore preventing the formation of membrane attack complex (C5b-C9). This molecule has shown potential for NMO treatment in a pilot open study with 14 patients\(^22\).

Other potentially valid treatment options, still pending adequate assessment, would be aquaporin 4 humabized NMO-IgG monoclonal antibody with high affinity which might prevent pathogenic aquaporine-4 from binding to the Fc fragment, alemtuzumab (anti-CD52 previously available as a plasmapheresis, or intravenous human immunoglobulin\(^7\).
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Way of administration</th>
<th>Potential risks</th>
<th>Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucocorticoids</td>
<td>IV in the acute stage Oral for maintenance</td>
<td>Hypoglycemia, hypertension, sleep and behaviour alterations, adrenal suppression, osteoporosis, osteonecrosis, myopathy, glaucoma, cataracts, GI alterations</td>
<td>Blood pressure, glycemic profile, ophthalmological evaluation, bone densitometry</td>
</tr>
<tr>
<td>Immunoglobulins</td>
<td>IV SC</td>
<td>Hypersensitivity alterations, thromboembolic events, renal failure, aseptic meningitis, hemolytic anemia, neutropenia</td>
<td>Vital signs during infusion, BUN and creatinine</td>
</tr>
<tr>
<td>Plasmapheresis</td>
<td>IV</td>
<td>Central line, hypocalcemia, arterial hypotension, arrhythmia, coagulopathy</td>
<td>Blood test, electrolytes, immunoglobulin levels, coagulation</td>
</tr>
<tr>
<td>Azathioprine</td>
<td>Oral</td>
<td>Liver toxicity, cytopenias, GI toxicity, alopecia, photosensitivity, risk of lymphoma</td>
<td>Blood test, liver profile, 5-mercaptopurine methyltransferase testing before treatment</td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>IV, oral</td>
<td>Nausea/vomiting, alopecia, mucositis, cystitis, teratogenicity, egg/spermatozoïd preservation due to lack of fertility</td>
<td>Blood test, renal function, urinestest</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>Oral</td>
<td>Nausea, diarrhea, mucositis, cytopenias, liver toxicity, pneumonitis, photosensitivity, teratogenicity</td>
<td>Blood test, liver profile, chest X-ray before treatment</td>
</tr>
<tr>
<td>Mitoxantrone</td>
<td>IV</td>
<td>Injection-site necrosis, arrhythmias, cardiopathy, cytopenias, liver toxicity, egg/spermatozoïd preservation due to lack of fertility, leukemia</td>
<td>Not exceeding the maximum dose of 140 mg/m², blood test, liver profile, ECG, echocardiogram</td>
</tr>
<tr>
<td>Mycophenolate mofetil</td>
<td>Oral</td>
<td>Nausea, diarrhea, abdominal pain, liver toxicity, cytopenias, hypertension, nephrotoxicity, coughing, dyspnea, headache, tremor, lymphoma and other neoplasia, teratogenicity</td>
<td>Blood test, liver profile, renal function</td>
</tr>
<tr>
<td>Tacrolimus</td>
<td>Oral</td>
<td>Headache, nephrotoxicity, hypertension, tremor, diarrhea, nausea/vomiting, insomnia, anorexia, distal paresthesias</td>
<td>Blood pressure, renal function</td>
</tr>
<tr>
<td>Interferon-β</td>
<td>SC, IM</td>
<td>Flu-like syndrome, injection-site reactions, uremic hemolytic syndrome, dysthyroidism, liver toxicity, depression</td>
<td>Blood test, renal function, liver profile, thyroid function</td>
</tr>
<tr>
<td>Glatiramer acetate</td>
<td>SC</td>
<td>Injection-site reactions, lipopatraphy, post-injection idiosyncratic reaction, lymphadenopathy</td>
<td>Not required</td>
</tr>
<tr>
<td>Fingolimod</td>
<td>Oral</td>
<td>PML, bradycardia at first dose, hypertension, lymphopenia, liver toxicity</td>
<td>Previous encephalic MRI, cardiac monitoring at first dose, blood test, liver profile, blood pressure</td>
</tr>
<tr>
<td>Teriflunomide</td>
<td>Oral</td>
<td>Liver toxicity, cytopenias, hypertension, lack of GI tolerability, alopecia, peripheral neuropathy, teratogenic</td>
<td>Blood pressure, blood test, liver profile</td>
</tr>
<tr>
<td>Dimethyl fumarate</td>
<td>Oral</td>
<td>Lack of GI tolerability, flushing, PML, cytopenia, liver toxicity</td>
<td>Previous encephalic MRI, blood test, liver profile</td>
</tr>
<tr>
<td>Natalizumab</td>
<td>IV</td>
<td>PML, hypersensitivity alterations at infusion</td>
<td>Previous encephalic MRI and periodical follow-up MRI, blood test, liver profile, anti-JCV testing every 6 months in seronegative patients</td>
</tr>
<tr>
<td>Alemtuzumab</td>
<td>IV</td>
<td>Hypersensitivity alterations at infusion, thrombopenia, dysthyroidism, glomerulonephritis</td>
<td>Blood test, liver profile, renal function, urine test, vital signs during infusion</td>
</tr>
<tr>
<td>Rituximab</td>
<td>IV</td>
<td>Hypersensitivity alterations, hypogammaglobulinaemia, PML, infusion reactions, edema, fever, headache</td>
<td>Vital signs during infusion, blood test, CD19/CD20 count, IgG/IgM levels</td>
</tr>
<tr>
<td>Ocrelizumab</td>
<td>IV</td>
<td>Hypersensitivity alterations at infusion, infections, neutropenia, reduction in IgM and IgG, coughing, ENT mucositis, cancer (breast)</td>
<td>Blood test, liver profile</td>
</tr>
<tr>
<td>Cladribine</td>
<td>Oral</td>
<td>Cytopenias (lymphopenia), liver toxicity, infections (herpes zoster)</td>
<td>Blood test, liver profile, watching for neoplasia</td>
</tr>
<tr>
<td>Tocilizumab</td>
<td>IV</td>
<td>Hypersensitivity alterations, GI perforation, liver toxicity, neutropenia, thrombopenia, TB reactivation</td>
<td>Blood test, liver profile</td>
</tr>
<tr>
<td>Eculizumab</td>
<td>IV</td>
<td>Hypersensitivity alterations, hypertension, anemia, meningococcial infection</td>
<td>Blood test, liver and renal profile</td>
</tr>
<tr>
<td>Infliximab</td>
<td>IV</td>
<td>Hypersensitivity alterations, liver toxicity, demyelination, Neuritis optica, TB reactivation</td>
<td>Vital signs during infusion, blood test, liver profile</td>
</tr>
</tbody>
</table>

ABUN: Blood urea nitrogen test; MRI: Magnetic resonance imaging; GI: Gastrointestinal; TB: Tuberculosis; PML: Progressive multifocal leuкоencephalopathy; ENT: Ear, nose and throat; ECG: Electrocardiogram; IgG: Immunoglobulin G; IgM: Immunoglobulin M; Anti-JCV: JC virus antibody test.
Migraine

Migraine is a highly prevalent neurological disease; 14.7% of the world population suffers it. It is the third most common disease in women and the second in men.

In the past decade, blocking the calcitonin gene-related peptide (CGRP) has been put forward as a new treatment target for preventing migraine episodes. This is due to the finding that CGRP levels increased during migraine episodes, and were reduced after using triptans. Moreover, the intravenous administration of CGRP caused migraine episodes in migraine patients. Two types of drugs have been designed in order to modify this CGRP design: on one hand, the CGRP receptor antagonists, the “gepants”; and on the other hand, monoclonal antibodies targeted to CGRP or its receptor. All these have demonstrated efficacy in controlled and randomized clinical trials, with efficacy at least equal to that of current preventive treatments.

In terms of safety, liver toxicity problems have been observed with some gepants; this does not seem to happen with monoclonal antibodies. Regarding the latter, in the absence of long-term data, some doubts can arise in terms of the cardiovascular system (hypertension, ischemic events), pituitary function, the GI system (constipation/diarrhea, ulcers, irritable bowel), and skin (erythema, inflammation, interference with wound healing). The potential presence of neutralizing antibodies which limit the effect of monoclonal antibodies must also be taken into account.

Autoimmune epilepsy

Alongside epilepsy conditions associated with systemic autoimmune disorders, such as systemic lupus erythematosus, Hashimoto encephalopathy, sarcoidosis or celiac disease, there are antibody-mediated disorders which cause epileptic episodes as one of their main clinical manifestations. Said antibodies can be classified into those that bind intracellular antigens and those that bind to neuronal surface proteins. The first class includes the Hu, Ma2, CRMP5 and amphiphysin antibodies. Those conditions derived of intracellular antigens will present a worse response to immunotherapy

Movement disorders

Movement disorders caused by an autoimmune physiopathology can appear isolatedly or within a wider encephalopathic process including epileptic manifestations and/or cognitive deterioration. Traditionally, movement disorders have been classified into “hyperkinetic” (myoclonus, chorea, tics, pseudoaethetosis, dystonia and other phenomena), and “hypokinetic” (Parkinsonism, stiff-person syndrome, progressive encephalomyelitis with rigidity and myoclonus). These are conditions with low prevalence (e.g. stiff person, 1/1,250,000). In their treatment, besides determining if there is a causal neoplasia and eliminating it, treatment consists in the use of intravenous methylprednisolone, intravenous human immunoglobulin, or plasmapheresis in the acute stage, and azathioprine and mycophenolate mofetil as maintenance therapy.

In this section, it is worth referring briefly to potential treatment targets in idiopathic Parkinson’s disease, a condition with a major prevalence (1/2/1,000). Physiopathological knowledge leads to consider that α-synuclein is a key molecule in neuronal death in Parkinson’s disease, by aggregating in toxic forms, spreading into the extracellular space and “contaminating” the adjacent neurons, thus perpetuating the pathogenic process. Thus, active or passive immunotherapy strategies intended to reduce the level of α-synuclein toxic extracellular aggregation could reduce or prevent the disease progression.

Autoimmune epilepsy

Alongside epilepsy conditions associated with systemic autoimmune disorders, such as systemic lupus erythematosus, Hashimoto encephalopathy, sarcoidosis or celiac disease, there are antibody-mediated disorders which cause epileptic episodes as one of their main clinical manifestations. Said antibodies can be classified into those that bind intracellular antigens and those that bind to neuronal surface proteins. The first class includes the Hu, Ma2, CRMP5 and amphiphysin antibodies. Those conditions derived of intracellular antigens will present a worse response to immunotherapy.

Overall, immune treatment consists in a first line with intravenous methylprednisolone 500-1,000 mg/day/5 days, while intravenous immunoglobulin or plasmapheresis are reserved for steroidresistant patients. Second line...
Dementia and autoimmune encephalopathies

The presentation form ranges from acute limbic encephalitis to subacute or chronic forms with a difficult differential diagnosis vs. primarily neurodegenerative conditions. Their etiology is primarily idiopathic-autoimmune or in the context of a paraneoplastic phenomenon. In terms of treatment, the main objective in paraneoplastic conditions is to remove the causal tumour completely, whenever possible. For any of both physiopathological mechanisms, however, acute treatment of neurological symptoms will be, as in other autoimmune conditions, intravenous methylprednisolone used at high doses, or intravenous human immunoglobulin. Improvement with acute treatment can justify the use of maintenance therapy with corticosteroids, azathioprine, mycophenolate mofetil, methotrexate or tacrolimus, among other agents. In some conditions, such as anti-N-methyl-d-aspartate receptor encephalitis, drugs like rituximab or cyclophosphamide can be considered second-line treatment when there is little or no response with previously mentioned agents. Acute disseminated encephalomyelitis, more frequent among pediatric patients, is a condition more typically monophasic, and therefore its management will usually be limited to acute treatment with intravenous methylprednisolone at high doses, intravenous human immunoglobulin, or plasmapheresis.

Alzheimer’s disease

The prevalence of Alzheimer’s disease increases with age. In an estimation conducted for 2017 in the United States of America, 4% of people <65-year-old present the disease, as well as 16% of persons between 65 and 74-year-old, 44% between 75 and 84-year-old, and 38% of people >85-year-old. It is expected that, at world level, the number of Alzheimer cases will triple by 2050. In an ageing society like ours in Spain, Alzheimer’s disease is already representing a major public health problem, and this will get even worse in the future.

The treatment for Alzheimer’s disease is based on those items considered key in its physiopathology, still only partly known (Table 3). A key event in this condition is the loss of cholinergic neurons, which has led to the prescription of cholinesterase inhibitors such as donepezil or rivastigmine. Another relevant element is the increase in glutamatergic activity, which has strengthened the indication of anti-N-methyl-D-aspartate receptor blockers such as memantine. Both therapeutic classes are typically used in current clinical practice. There are other three physiopathological mechanisms that can open new therapeutic targets, this time through the use of immunotherapies. The build-up of neuritic plaques (β-amyloid), neurofibrillary tangles (τ protein), and the local inflammation caused by microglia, are potential treatment objectives that are being evaluated in recent years.

β-amyloid plaque is formed in two steps from the amyloid precursor protein (APP), through the β-secretase and γ-secretase enzyme complexes. It is thought that β-amyloid deposit could play a major role in the development of Alzheimer’s disease. Keeping this hypothesis in mind, there has been a development, on one hand, of therapies able to reduce the activity of the β-secretase and γ-secretase complexes, with the objective of producing less β-amyloid; and, on the other hand, immunological treatments that can increase the elimination of the pathogenic β-amyloid already formed.

Thus, two strategies have been developed: active immunotherapy and passive immunotherapy. One of the first clinical trials on active immunotherapy was conducted with AN1-792, a synthetic amyloid peptide (Aβ1-2), which induces the production of antibodies against the β-amyloid. The Phase II clinical trial was stopped due to the development of meningoencephalitis in 6% of the study subjects. Besides, in those who did not develop meningoencephalitis, there was no demonstrated delay in the evolution of cognitive deterioration, despite a clear reduction in the senile plaque deposits. In view of these results, it was argued that the study included patients with moderate/severe Alzheimer’s disease, maybe treatment with drugs promoting the elimination of senile plaques could be indicated in earlier stages of the disease. With this recommendation, other molecules promoting active immunity to eliminate the amyloid plaques are being evaluated: among them, agent CAD106, safe and well tolerated, without any meningoencephalitis cases reported to date, is still under study. Regarding passive immunotherapy, various molecules have been developed and are currently under evaluation. Bapineuzumab, targeting the N-terminal end of β-amyloid, has been discontinued due to its low efficacy and negative safety profile at Phase III. On the other hand, solanezumab, which targets the monomer soluble β-amyloid, has presented an adequate safety profile, and it is being evaluated in patients with very early forms of Alzheimer’s disease. It has demonstrated an increase in β-amyloid-42 soluble protein in the cerebrospinal fluid of patients, with dose-dependent effect, which would support its mechanism of action of β-amyloid deposit elimination. However, it has not demonstrated clinical efficacy in mild Alzheimer’s disease. Aducanumab is also on Phase III clinical trials, used for mild Alzheimer’s disease, but also for the mild cognitive impairment stage. Finally, gantenerumab, which interacts with β-amyloid fibrils to recruit microglia, activate phagocytosis and degrade neurofibrillary plaques, is currently in early stages of clinical development; it has shown an adequate safety profile, and is pending efficacy outcomes in mild Alzheimer’s disease and mild cognitive impairment.

Similarly as with neurtic plaques, the presence of neurofibrillary tangles formed by hyperphosphorylated τ protein seems to be one of the key elements responsible for pathogenesis in Alzheimer’s disease. Aggregated τ protein is cytotoxic; therefore, preventing its production or favoring its elimination could have a clinical effect on patients. As it has been mentioned for β-amyloid protein, there are molecules which could lead to the elimination of pathogenic τ protein, through active immunotherapy. AADvac1, an active vaccine with a natural truncated form of human τ protein, through active immunotherapy. AADvac-1, an active vaccine with a natural truncated form of human τ protein, through active immunotherapy. AADvac-1, an active vaccine with a natural truncated form of human τ protein, through active immunotherapy.
after having shown a good safety profile. C2NBE12 is a humanized anti-β-amyloid antibody currently on Phase II study, and safety and efficacy outcomes are expected for 202011.

Besides neuritic plaques (β-amyloid) and neurofibrillary tangles (τ), neuroinflammation is one of the key elements in the physiopathology of Alzheimer’s disease. Evident astrogliosis has been observed, among other signs of inflammation, around amyloid plaques, and various studies suggest a relationship between microglia activation, neuritic plaque formation, and the clinical progression of the disease. For this reason, a therapy targeted to inhibit the activation of microglia could be useful. However, negative results with tramiprosate (lack of efficacy at Phase III), ibuprofen and rilubuprofen, have reduced the expectations for this therapeutic group / mechanism of action. CHF 5074 is still on Phase II clinical trials: a microglia modulator for patients with mild cognitive impairment12.

Finally, it is worth pointing out that intravenous human immunoglobulin seems to be effective for maintaining the cognitive ability in patients with mild to moderate Alzheimer’s disease in Phase III clinical trials13.

Peripheral nervous system

- GBS: An acute sensory-motor polyradiculopathy, demyelinating, axonal or mixed, with inflammatory origin. The typical symptoms are paresthesia, pain and loss of strength, though there are different clinical forms such as Miller Fisher syndrome, a sensory ataxia condition with involvement in the brain stem and oculomotor nerves. Its incidence is of 0.4 to 3.25 patients per 1,000,000 inhabitants and year14. GBS is treated with plasmapheresis; its efficacy was confirmed in Cochrane’s 2012 review15. An alternative option is using intravenous human immunoglobulin at 0.4 g/kg/ day during 5 days. No placebo-controlled studies have been conducted, but a Cochrane review from 2014 confirmed its efficacy, comparable to plasmapheresis, after a systematic evaluation of 5 clinical trials16. Besides, two clinical trials confirmed similar efficacy but fewer side effects of immunoglobulin vs. plasmapheresis17,18. A complete review on this matter can be consulted in the article by Vrijdicks and Klein19.

- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Considered the chronic presentation (> 8 weeks of duration) of the demyelinating form of GBS, its treatment also consists in the use of plasmapheresis or immunoglobulin. However, while glucocorticoids are considered ineffective in GMS, these are useful both in the acute stage and the maintenance treatment of CIDP20. Rituximab has shown efficacy in studies with small patient cohorts with this condition21,22. Eculizumab could be an option still not tested in CIDP. Fringilimomab and alemtuzumab23 could play a role in the treatment of this disease, pending confirmation in randomized and controlled clinical trials.

- Multifocal motor neuropathy (MMN) is an autoimmune disorder with low prevalence (0-6.2 patients per 100,000 inhabitants)24. It causes a slowly progressive loss of strength, asymmetrical and mainly distal. MMN is mediated by antiganglioside antibodies, and it can be treated with human intravenous or subcutaneous immunoglobulin, thus improving its symptoms and preventing their progression. Four clinical trials25,26 have demonstrated that 78% of patients treated with intravenous immunoglobulin improved significantly their motor ability vs. 4% treated with placebo. Even though the metanalysis of said studies did not show significant differences in the improvement of disability27, the treatment guidelines by the European Federation of Neurological Societies (EFNS) recommend using 2 g/kg of intravenous human immunoglobulin for first line treatment of MMN; this dose must be administered over 2 to 5 days. These guidelines also state that the maintenance dose of intravenous human immunoglobulin to be administered after an initial improvement with the first cycle should be 1 g/kg every 2 to 4 weeks, or 2 g/kg every 12 months28. It is worth noting that subcutaneous immunoglobulin has demonstrated similar efficacy to the intravenous formulation in MMN treatment, both for early stages29 as well as maintenance30. For an exhaustive review about this, it is recommended to read the work by Kumar et al.31.

- Amyotrophic lateral sclerosis (ALS) is a degenerative motor neuron disease. Physiopathological mechanisms of immunological substrate have recently been mentioned, thus opening a potential pathway for immunotherapy treatment. A review on this topic32 describes the use of treatments for Rheumatoid Arthritis: anakinra (a recombinant analog of the interleukin-1 receptor antagonist), with negative outcomes; matinib (a tyrosine-kinase inhibitor), with an ongoing Phase III clinical trial, and tocilizumab, also under clinical trial, in this phase Case II. Treatments for MS have also been used, such as glatiramer acetate (negative outcomes) or fingolimod (efficacy not demonstrated). The lack of efficacy outcomes obtained with intravenous immunoglobulin, celecoxib, oza-neumab, NP001 (tauine), thalidomide, granulocyte stimulating factor, cyclosporine, or total lymphoid irradiation, have not prevented continuing with the line of research of immunological therapies for ALS. Other agents, such as ibudilast to TLR4 and pro-caspase-3, have also been included. In patients with mild cognitive impairment33.

Finaly, it is worth pointing out that intravenous human immunoglobulin seems to be effective for maintaining the cognitive ability in patients with mild to moderate Alzheimer’s disease in Phase III clinical trials34.

Discussion

Currently, immunological treatments allow us to treat a high number of neurological conditions in a more accurate and individualized way. The trend of precise treatment targeting specific pathways in clinical trials with high level of evidence has become more frequent in clinical practice. Moreover, the range of conditions that can be potentially treated with immunotherapy is increasingly higher, and has started to include highly prevalent neurological conditions such as migraine and, possibly, Alzheimer’s disease. The high impact that these therapies could entail for
public health system will require compromises and consensus by all actors involved in their adequate use.

**Funding**

No funding.

---

**Bibliography**


